Dry powder inhalation: past, present and future

References

• Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care. 2005;50:1139–1149.
   PubMedGoogle Scholar
• Dessanges J. A history of nebulization. J Aerosol Med. 2001;14:65–71.
   PubMedGoogle Scholar
• Grossman J. The evolution of inhaler technology. J Asthma. 1994;31:55–64.
   PubMed Web of Science ®Google Scholar
• Sanders M. Inhalation therapy: an historical review. Primary Care Respir J. 2007;16(2):71–81.
   PubMedGoogle Scholar
• Cutchis P. Stratospheric ozone depletion and solar ultraviolet radiation on earth. Science. 1974;184:13–19.
   PubMed Web of Science ®Google Scholar
• Lovelock JE. Halogenated hydrocarbons in the atmosphere. Ecotoxicol Environ Saf. 1977;1:399–346.
   PubMed Web of Science ®Google Scholar
• Noakes TJ. CFCs, their replacement, and the ozone layer. J Aerosol Med. 1995;8:S3–S7.
   PubMedGoogle Scholar
• D’Souza S. The montreal protocol and essential use exemptions. J Aerosol Med. 1995;8:S13–S17.
   PubMedGoogle Scholar
• The London Gazette. 1864 Aug vol. 16. 4044.
   Google Scholar
• Robson RA, Taylor BJ, Taylor B. Sodium cromoglycate: Spincaps or metered dose aerosol. Br J Clin Pharm. 1981;11:383–384.
   PubMed Web of Science ®Google Scholar
• Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I: a new inhaler device. J Pharm Sci. 1971;60:1559–1564.
   PubMed Web of Science ®Google Scholar
• Hall VC. Inhaler. US patent 2517482. 1950.
   Google Scholar
• Ellis MC. Device for dispensing medicaments. US patent 2573918. 1951.
   Google Scholar
• Cocozza S. Inhaling device for medial powder compositions. US patent 3807400. 1974.
   Google Scholar
• Mathes S. Inhalation device. US patent 3938516. 1976.
   Google Scholar
• Wilke GA, Henderson NC, Stansel SM, et al. Inhalation device. US patent 3948264. 1976.
   Google Scholar
• Valentini L, Maiorano N. Inhalation device. US patent 4069819. 1978.
   Google Scholar
• Clark AR. Medical aerosol inhalers: past, present and future. Aerosol Sci Technol. 1995;22:374–391.
   Web of Science ®Google Scholar
• Pover GM, Dash CH. A new modified form of inhaler (“Rotahaler”) for patients with chronic obstructive lung disease. Pharmatherapeutica. 1985;4:98–101.
   PubMedGoogle Scholar
• Kladders H. Powdered pharmaceutical inhaler. US patent 4889114. 1989.
   Google Scholar
• Cocozza S. Inhaler for powdered medicaments. US patent 3991761. 1976.
   Google Scholar
• Jones TM, Pilpel N. Some physical properties of lactose and magnesia. J Pharm Pharmacol. 1965;17:440–448.
   PubMed Web of Science ®Google Scholar
• Shotton E, Orr NA. Studies on mixing cohesive powders. J Pharm Pharmacol Suppl. 1971;23(S1):260S.
   PubMedGoogle Scholar
• Travers DN, White RC. The mixing of micronised sodium bicarbonate with sucrose crystals. J Pharm Pharmacol Suppl. 1971;23(S1):260S–261S.
   PubMedGoogle Scholar
• Hersey JA. Ordered mixing: a new concept in powder mixing. Powder Technol. 1975;7:41–44.
   Web of Science ®Google Scholar
• Staniforth JN. Order out of chaos. J Pharm Pharmacol. 1987;39:329–334.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Gjaltema D, et al. Air classifier technology (ACT) in dry powder inhalation Part 3: Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler. Int J Pharm. 2006;310:72–80.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Gjaltema D, et al. Air classifier technology (ACT) in dry powder inhalation Part 4: Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. Int J Pharm. 2006;310:81–89.
   PubMed Web of Science ®Google Scholar
• Newman SP, Pitcarin GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J. 2000;16:178–183.
   PubMed Web of Science ®Google Scholar
• Nieminen MM, Vidgren M, Laurikainen K, et al. Easyhaler, a novel multiple dose powder inhaler: clinically equivalent to salbutamol metered dose inhaler and easier to use. Respiration. 1994;61:37–41.
   PubMed Web of Science ®Google Scholar
• Meakin BJ, Ganderton D, Panza I, et al. The effect of flow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler. J Aerosol Med. 1998;11:143–152.
   PubMedGoogle Scholar
• Overhoff KA, Clayborough R, Crowley M. Review of the TAIFUN multidose dry powder technology. Drug Dev Ind Pharm. 2008;34:960–965.
   PubMed Web of Science ®Google Scholar
• Lankinen T. Device intended for measuring a dose of powdered medicament for inhalation. US patent RE35552. 1997.
   Google Scholar
• Ambrosio TJ, Ashley CR, Bilanin AJ, et al. Inhaler for powdered medications. WO patent 94/14492. 1994.
   Google Scholar
• Newhouse MT, Nantel NP, Chambers CB, et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest. 1999;115:952–956.
   PubMed Web of Science ®Google Scholar
• Dahl R, Creemers JP, Van Noord J, et al. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the aerolizer dry powder inhaler in patients with persistent asthma. Respiration. 2004;71:126–133.
   PubMed Web of Science ®Google Scholar
• Middle MV, Terblanché J, Perrin VL, et al. Bronchodilating effects of salbutamol from a novel inhaler Airmax. Resp Med. 2002;96:493–498.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Arp J, Keegstra JR, et al. Spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions. J Aerosol Med Pulm Drug Deliv. 2015;28:309–319.
   PubMed Web of Science ®Google Scholar
• Sumby BS, Churcher KM, Smith IJ, et al. Dose reliability of the serevent diskhaler system. PharmTech Int. 1993;5:20–27.
   Google Scholar
• Brindley A, Sumby BS, Smith IJ, et al. Design, manufacture and dose consistency of the serevent diskus inhaler. Pharm Technol Eur. 1995;7:14–22.
   Google Scholar
• Wetterlin K. Turbuhaler: a new dry powder inhaler for administration of drugs to the airways. Pharm Res. 1988;5:506–508.
   PubMed Web of Science ®Google Scholar
• Crompton GK. Dry powder inhalers: advantages and limitations. J Aerosol Med. 1991;4:151–156.
   PubMedGoogle Scholar
• LiCalsi C, Christensen T, Bennett JV, et al. Dry powder inhalation as a potential delivery method for vaccines. Vaccine. 1999;17:1796–1803.
   PubMed Web of Science ®Google Scholar
• White S, Bennett DB, Chey S, et al. EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther. 2005;7:896–906.
   PubMedGoogle Scholar
• Han R, Papadopoulos G, Greenspan BJ. Flow field management inside the mouthpiece of the spiros inhaler using particle image velocimetry. Aerosol Sci and Technol. 2002;36:329–341.
   Web of Science ®Google Scholar
• Virchov JC. What plays a role in the choice of inhaler device for asthma therapy. Curr Med Res Opin. 2005;21:S19–S25.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377:1032–1045.
   PubMed Web of Science ®Google Scholar
• Laube BL, Janssens HM, De Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Resp J. 2011;37:1308–1331.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–1504.
   PubMed Web of Science ®Google Scholar
• Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Resp Med. 2014;108:1195–1203.
   PubMed Web of Science ®Google Scholar
• Norman P. Developments in inhaled combination therapies: patent activity 2013-2014. Expert Opin Ther Patents. 2015;25:1239–1245.
   PubMed Web of Science ®Google Scholar
• Flenly DC. Today’s treatment of airway obstruction.and tomorrow’s? Respiration. 1989;55(Suppl.2):4–9.
   PubMedGoogle Scholar
• Prime D, Atkins PJ, Slater A, et al. Review of dry powder inhalers. Adv Drug Deliv Rev. 1997;26:51–58.
   PubMed Web of Science ®Google Scholar
• Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market. Pulm Pharmacol Ther. 2003;16:79–95.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2: effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm. 1996;138:45–46.
   Web of Science ®Google Scholar
• Pauwels R, Newman S, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered dose inhalers. Eur Respir J. 1997;10:2127–2138.
   PubMed Web of Science ®Google Scholar
• Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? J Aerosol Med. 1995;8:S13–S18.
   PubMedGoogle Scholar
• Borgström L, Derom E, Ståhl E, et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med. 1996;153:1636–1640.
   PubMed Web of Science ®Google Scholar
• Frijlink HW, de Boer AH. Dry powder inhalers for pulmonary drug delivery. Exp Opin Drug Deliv. 2004;1:67–86.
   PubMedGoogle Scholar
• Clark AR, Newman SP, Dasovich N. Mouth and oropharyngeal deposition of pharmaceutical aerosols. J Aerosol Med. 1998;11:S116–S121.
   PubMedGoogle Scholar
• DeHaan WH, Finlay WH. Predicting extrathoracic deposition from dry powder inhalers. Aerosol Sci. 2004;35:309–331.
   Web of Science ®Google Scholar
• de Boer AH, Chan HK, Price R. A critical view on lactose-based drug formulation and device studies for powder inhalation; Which are relevant and what interactions to expect. Adv Drug Deliv Rev. 2012;64:257–274.
   PubMed Web of Science ®Google Scholar
• Grasmeijer F, Grasmeijer N, Hagedoorn P, et al. Recent advances in the fundamental understanding of adhesive mixtures for inhalation. Curr Phar Design. 2015;21:5900–5914.
   PubMed Web of Science ®Google Scholar
• Islam N, Stewart P, Larson I, et al. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J Pharm Sci. 2004;93:1030–1038.
   PubMed Web of Science ®Google Scholar
• Guenette E, Barrett A, Kraus D, et al. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Int J Pharm. 2009;380:80–88.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Serigano T, Hino T, et al. Effect of surface morphology of carrier lactose on dry powder inhalation of pranlukast hydrate. Int J Pharm. 1998;172:179–188.
   Web of Science ®Google Scholar
• Ferrari F, Cocconi D, Bettini R, et al. The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer. AAPS PharmSciTech. 2004;5:69–74.
   Web of Science ®Google Scholar
• Kayali W, Ticehurst MD, Murphy J, et al. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone. J Pharm Sci. 2011;100:2665–2684.
   PubMed Web of Science ®Google Scholar
• Arnold K, Grass P, Knecht A, et al. Powders for inhalation. US patent 5478578. 1995.
   Google Scholar
• Jones MD, Price R. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res. 2006;23:1665–1674.
   PubMed Web of Science ®Google Scholar
• Begat P, Morton DAV, Staniforth JN, et al. The cohesive-adhesive balances in dry powder inhaler formulations I: direct quantification by atomic force microscopy. Pharm Res. 2004;21:1591–1597.
   PubMed Web of Science ®Google Scholar
• Tong HY, Shekunov BY, York P, et al. Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids. Pharm Res. 2001;18:852–858.
   PubMed Web of Science ®Google Scholar
• Sitz R. Current innovations in dry powder inhalers. Ondrugdelivery. 2010:10–12. Available from: www.ondrugdelivery.com
   Google Scholar
• Newman S, Malik S, Hirst P, et al. Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. Respir Med. 2002;96:1026–1032.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Gjaltema D, Hagedoorn P, et al. Comparative in vitro performance evaluation of the novopulmon 200 novolizer and budesonid-ratiopharm jethaler: two novel budesonide dry powder inhalers. Pharmazie. 2004;59:692–699.
   PubMed Web of Science ®Google Scholar
• Alhalaweh A, Kaialy W, Buckton G, et al. Theofylline cocrystals prepared by spray drying: physicochemical properties and aerosolization performance. AAPS PharmSciTech. 2013;14:265–276.
   PubMed Web of Science ®Google Scholar
• Padrela L, Rodrigues MA, Tiago J, et al. Tuning physiochemical properties of theofylline by cocrystallization using the super critical fluid enhanced atomization technique. J Supercritical Fluids. 2014;86:129–136.
   Web of Science ®Google Scholar
• Velaga SP, Berger R, Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide. Pharm Res. 2002;19:1564–1571.
   PubMed Web of Science ®Google Scholar
• Rehman M, Shekunov BY, York P, et al. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sci. 2004;22:1–17.
   PubMed Web of Science ®Google Scholar
• Buckton G. Characterisation of small changes in the physical properties of powders of significance for dry powder inhalation formulations. Adv Drug Deliv Rev. 1997;26:17–27.
   PubMed Web of Science ®Google Scholar
• Staniforth JN. Carrier particles for use in dry powder inhalers. WO patent 1996023485. 1996.
   Google Scholar
• Begat P, Morton DA, Shur J, et al. The role of force control agents in high-dose dry powder inhaler formulations. J Pharm Sci. 2009;98:2770–2783.
   PubMed Web of Science ®Google Scholar
• Das SC, Zhou Q, Morton DA, et al. Use of surface energy distributions by inverse gas chromatography to understand mechanofusion processing and functionality of lactose coated with magnesium stearate. Eur J Pharm Sci. 2011;43:325–333.
   PubMed Web of Science ®Google Scholar
• Grant AC, Walker R, Hamilton M, et al. The `ELLIPTA dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015;28:474–485.
   PubMed Web of Science ®Google Scholar
• Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26:2527–2533.
   PubMed Web of Science ®Google Scholar
• Staniforth JN, Morton DA, Brambilla G, et al. Pharmaceutical formulations foer dry powder inhalers in the form of hard-pellets. WO 01/78693. 2001.
   Google Scholar
• Cocconi D, Alberti MD, Busca A, et al. Use of magnesium stearate in dry powder formulations for inhalation. US patent 20120082727. 2012.
   Google Scholar
• Corradi M, Chrystyn H, Cosio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclomethasone and formoterol to treat large and small airways in asthma. Exp Opin Drug Deliv. 2014;11:1497–1506.
   PubMed Web of Science ®Google Scholar
• Buttini F, Brambilla G, Copelli D, et al. Effect of flow rate on in vitro aerodynamic performance of NEXThaler in comparison with diskus and turbuhaler dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28:1–12.
   PubMed Web of Science ®Google Scholar
• Glover W, Chan H-K, Eberl S, et al. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J Pharm. 2008;349:314–322.
   PubMed Web of Science ®Google Scholar
• Bosquillon C, Lombry C, Préat V, et al. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release. 2001;7:329–339.
   Web of Science ®Google Scholar
• Li H-Y, Seville PC, Williamson IJ, et al. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J Gene Med. 2005;7:343–353.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Vanderbist F, Amighi K. Spray-dried carrier free dry powder tobramycin formulations with improved dispersion properties. J Pharm Sci. 2009;98:1463–1475.
   PubMed Web of Science ®Google Scholar
• Duddu SP, Sisk SA, Walter YH, et al. Improved lung delivery from a passive dry powder inhaler using an engineered pulmosphere powder. Pharm Res. 2002;19:689–696.
   PubMed Web of Science ®Google Scholar
• Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest. 2003;124:360–366.
   PubMed Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering by spray drying. Pharm Res. 2008;25:999–1022.
   PubMed Web of Science ®Google Scholar
• Schüle S, Schulz-Fademrecht T, Garidel P, et al. Stabilization of IgG1 in spray-dried powders for inhalation. Eur J Pharm Biopharm. 2008;69:793–807.
   PubMed Web of Science ®Google Scholar
• Saluja V, Amorij JP, Kapteyn JC, et al. A comparison between spray drying and spray freeze drying to produce influenza subunit vaccine powder for inhalation. J Control Release. 2010;144:127–133.
   PubMed Web of Science ®Google Scholar
• Shoyele SA, Sivadas N, Cryan S-A. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as dry powder for inhalation. AAPS PharmSciTech. 2011;12:304–311.
   PubMed Web of Science ®Google Scholar
• Adouy SA, van der Schaaf G, Hinrichs WL, et al. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine. 2011;29:4345–4352.
   PubMed Web of Science ®Google Scholar
• Bürki K, Jeon I, Arpagaus C, et al. New insights into inspirable protein powder preparation using a nano spray dryer. Int J Pharm. 2011;408:248–256.
   PubMed Web of Science ®Google Scholar
• Fiegel J, Fu J, Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J Control Release. 2004;96:411–423.
   PubMed Web of Science ®Google Scholar
• Chougule M, Padhi B, Misra A. Development of spray dried liposomal dry powder inhaler of dapsone. AAPS PharmSciTech. 2008;9:47–53.
   PubMed Web of Science ®Google Scholar
• Bi R, Shao W, Wang Q, et al. Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. J Biomed Nanotechnol. 2009;5:84–92.
   PubMed Web of Science ®Google Scholar
• Scalia S, Salama R, Young P, et al. Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. J Microencapsul. 2012;29:225–233.
   PubMed Web of Science ®Google Scholar
• d’Angelo I, Casciaro B, Miro A, et al. Overcoming barriers in Pseudomonas lung infections: engineered nanoparticles for local delivery of a cationic antimicrobial peptide. Colloids Surf B Biointerfaces. 2015;135:717–725.
   PubMed Web of Science ®Google Scholar
• Manca ML, Valenti D, Sales OD, et al. Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin. Int J Pharm. 2014;472:102–109.
   PubMed Web of Science ®Google Scholar
• Amidi M, Pellikaan HC, de Boer AH, et al. Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary drug delivery. Eur J Pharm Biopharm. 2008;68:191–200.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res. 2006;23:931–940.
   PubMed Web of Science ®Google Scholar
• Colombo G, Terzano C, Colombo P, et al. Methacholine dry powder inhaler as a new tool for bronchial challenge test. Int J Pharm. 2008;352:165–171.
   PubMed Web of Science ®Google Scholar
• Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary delivery. Science. 1997;276:1868–1871.
   PubMed Web of Science ®Google Scholar
• Sharma R, Saxena D, Dwivedi D, et al. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pham Res. 2001;18:1405–1410.
   PubMed Web of Science ®Google Scholar
• Gupta A, Pant G, Mitra K, et al. Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol Pharm. 2014;11:1201–1207.
   PubMed Web of Science ®Google Scholar
• Patel B, Gupta N, Ahsan F. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. Eur J Pharm Biopharm. 2015;89:163–174.
   PubMed Web of Science ®Google Scholar
• Tian G, Longest WP, Li X, et al. Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm Drug Deliv. 2013;26:248–265.
   PubMed Web of Science ®Google Scholar
• Son Y-T, Longest WP, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG). Application: effect of spray drying process conditions on aerosol performance. Int J Pharm. 2013;443:137–145.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392:1–19.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm. 2013;86:23–30.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31.
   PubMed Web of Science ®Google Scholar
• Claus S, Schoenbrodt T, Weiler C, et al. Novel dry powder inhalation system based on dispersion of lyophilisates. Eur J Pharm Sci. 2011;43:32–40.
   PubMed Web of Science ®Google Scholar
• Otake H, Okuda T, Okamoto H. Development of spray-freeze-dried powders for inhalation with high inhalation performance and antihygroscopic property. Chem Pharm Bull. 2016;64:239–245.
   PubMed Web of Science ®Google Scholar
• Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv. 2011;24:175–182.
   PubMed Web of Science ®Google Scholar
• Belotti S, Rossi A, Colombo P, et al. Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. Int J Pharm. 2014;471:507–515.
   PubMed Web of Science ®Google Scholar
• Borgström L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473–483.
   PubMedGoogle Scholar
• Stapleton KW, Guentsch F, Hoskinson MK, et al. On the suitability of k-turbulence modelling for aerosol deposition in the mouth and throat: a comparison with experiment. J Aerosol Sci. 2000;31:739–749.
   Web of Science ®Google Scholar
• Zhou Y, Sun J, Cheng Y-S. Comparison of deposition in the USP and physical mouth-throat models with solid and liquid particles. J Aerosol Med Pulm Drug Deliv. 2011;24:277–284.
   PubMed Web of Science ®Google Scholar
• Janssens HM, De Jongste JC, Fokkens WJ, et al. The sophia anatomical infant nose-throat (SAINT) model: A valuable tool to study aerosol deposition in infants. J Aerosol Med. 2001;14:433–441.
   PubMedGoogle Scholar
• DeHaan WH, Finlay WH. In vitro monodisperse aerosol deposition in mouth and throat with six different inhalation devices. J Aerosol Med. 2001;14:361–367.
   PubMedGoogle Scholar
• Lindert S, Below A, Breitkreutz J. Performance of dry powder inhalers with single dosed capsules in preschool children and adults with improved upper airway models. Pharmaceutics. 2014;6:36–51.
   PubMedGoogle Scholar
• Gerrity TR, Lee PS, Hass FJ, et al. Calculated deposition of inhaled particles in the airway generations of normal subjects. J Appl Physiol. 1979;47:867–873.
   PubMed Web of Science ®Google Scholar
• Weibel ER, Gomez DM. Architecture of the human lung. Use of quantitative methods establishes fundamental relations between size and number of lung structures. Science. 1962;137:577–585.
   PubMed Web of Science ®Google Scholar
• Newman S, Steed K, Hooper G, et al. Comparison of gamma scintigraphy and pharmacokinetic technique for asessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm Res. 1995;12:231–236.
   PubMed Web of Science ®Google Scholar
• Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatric Pulmonol. 2007;42:307–313.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Akkerman OW, Hagedoorn P, et al. Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. PloS ONE. 2016;11:e0149768. doi:10.1371/journal.pone.0149768.
   PubMed Web of Science ®Google Scholar
• Newman SP, Pitcairn GR, Hirst PH, et al. History of gamma scintigraphy. J Aerosol Med. 2001;14:139–145.
   PubMedGoogle Scholar
• Snell NJ, Ganderton D. Assessing lung deposition of inhaled medications. Respir Med. 1999;93:123–133.
   PubMed Web of Science ®Google Scholar
• Conway J. Lung imaging - Two dimensional gamma scintigraphy, SPECT, CT and PET. Adv Drug Deliv Rev. 2012;64:357–368.
   PubMed Web of Science ®Google Scholar
• Newman S, Fleming J. Challenges in assessing regional distribution of inhaled drug in the human lungs. Expert Opin Drug Deliv. 2011;8:841–855.
   PubMed Web of Science ®Google Scholar
• Scheuch G, Bennett W, Borgström L, et al. Deposition, imaging and clearance: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S39–S57.
   PubMed Web of Science ®Google Scholar
• Fleming J, Bailey DL, Chan HK, et al. Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25:S29–S51.
   PubMed Web of Science ®Google Scholar
• Corcoran TE, Davadason SG, Kuell PJ. Introduction: aerosol delivery of orally inhaled agents. J Aerosol Med Pulm Drug Deliv. 2012;25:S3–S5.
   PubMed Web of Science ®Google Scholar
• Laube BL, Corcoran TE, Davadason SG, et al. Editorial: standards for lung imaging techniques. J Aerosol Med Pulm Drug Deliv. 2012;25:S1–S2.
   PubMed Web of Science ®Google Scholar
• Conway J, Fleming J, Bennett M, et al. The co-imaging of gamma camera measurements of aerosol deposition and respiratory anatomy. J Aerosol Med Pulm Drug Deliv. 2013;26:123–130.
   PubMed Web of Science ®Google Scholar
• De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257:854–862.
   PubMed Web of Science ®Google Scholar
• Van Holsbeke CS, Leemans G, Vos WG, et al. Functional respiratory imaging as a tool to personalize respiratory treatment in patients with unilateral diaphragmic paralysis. Resp Care. 2014;59:e127–e131.
   PubMed Web of Science ®Google Scholar
• Cohn ML, Davis CL, Middlebrook G. Airborne immunization against tuberculosis. Science. 1967;158:1282–1283.
   Google Scholar
• Tonnis WF, Kersten GF, Frijlink HW, et al. Pulmonary vaccine delivery: a realistic approach? J Aerosol Med Pulm Drug Deliv. 2012;25:1–12.
   PubMed Web of Science ®Google Scholar
• Tonnis WT, Lexmond AJ, Frijlink HW, et al. Devices and formulations for pulmonary vaccination. Expert Opin Drug Deliv. 2013;10:1383–1397.
   PubMed Web of Science ®Google Scholar
• Pedersen S. Inhaler use in children with asthma. Dan Med Bull. 1987;34:234–249.
   PubMed Web of Science ®Google Scholar
• Lexmond AJ, Kruizinga TJ, Hagedoorn P, et al. Effect of inhaler design variables on pediatric use of dry powder inhalers. PLoS ONE. 2014;19(6). doi:10.1371/journal.pone.0099304.
   Web of Science ®Google Scholar
• Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic delivery. Proc Am Thorac Soc. 2004;1:338–344.
   PubMedGoogle Scholar
• Patton JS, Brain JD, Davies LA, et al. The particle has landed – characterizing the fate of inhaled pharmaceuticals. J Aerosl Med Pulm Drug Deliv. 2010;23:S71–S87.
   PubMed Web of Science ®Google Scholar
• Rogueda PG, Traini D. The nanoscale in pulmonary delivery. Part I: deposition, fate, toxicology and effects. Exp Opin Drug Deliv. 2007;4:595–606.
   PubMed Web of Science ®Google Scholar
• Ali ME, Lamprecht A. Spray freeze drying for dry powder inhalation of nanoparticles. Eur J Pharm Biopharm. 2014;87:510–517.
   PubMed Web of Science ®Google Scholar
• Willis L, Hayes D Jr, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190:251–262.
   PubMed Web of Science ®Google Scholar
• Mack P, Horvath K, Garcia A, et al. Particle Engineering for Inhalation Formulation and Delivery of Biotherapeutics. Inhalation. 2012 Aug. Available from: www/inhalationmag.com
   Google Scholar
• de Boer AH, Hagedoorn P, Westerman WM, et al. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses. Eur J Pharm Sci. 2006;28:171–178.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Akkerman OW, Hagedoorn P, et al. The Cyclops for pulmonary delivery of aminoglycosides: a new member of the twincer family. Eur J Pharm Biopharm. 2015;90:8–15.
   PubMed Web of Science ®Google Scholar
• Young PM, Salama RO, Zhu B, et al. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. Drug Develop Ind Pharm. 2015;41:859–865.
   PubMed Web of Science ®Google Scholar
• Young PM, Crapper J, Phillips G, et al. Overcoming dose limitations using the Orbital multi-breath dry powder inhaler. J Aerosol Med Pulm Drud Deliv. 2014;27:138–147.
   PubMed Web of Science ®Google Scholar
• Farkas DR, Hindle M, Longest PW. Characterization of a new high-dose dry powder inhaler (DPI) based on fluid bed design. Ann Biomed Eng. 2015;43:2804–2815.
   PubMed Web of Science ®Google Scholar
• Dinh K, Myers DJ, Glazer M, et al. In vitro aerosol characterization of staccato loxapine. Int J Pharm. 2011;403:101–108.
   PubMed Web of Science ®Google Scholar
• Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther. 2007;9:S65–S72.
   PubMed Web of Science ®Google Scholar
• Kling J. Dreamboat sinks prospects for fast approval of inhaled insulin. Nat Biotechnol. 2011;29:176–176.
   Web of Science ®Google Scholar
• Lipp MM, Sung JC. Monovalent metal cation dry powders for inhalation. US0231066A1. 2015.
   Google Scholar
• Lexmond AJ, Hagedoorn P, van der Wiel E, et al. Adenosine dry powder inhalation for bronchial challenge testing, part 1: Inhaler and formulation development and in vitro performance testing. Eur J Pharm Biopharm. 2014;86:105–114.
   PubMed Web of Science ®Google Scholar
• Anderson SD, Brannan J, Spring J, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med. 1997;156:758–765.
   PubMed Web of Science ®Google Scholar
• Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med. 1994;7:49–75.
   PubMedGoogle Scholar
• Laube BL. Aerosolized medications for gene and peptide therapy. Resp Care. 2015;60:806–821.
   PubMed Web of Science ®Google Scholar
• McElroy MC, Kirton C, Gliddon D, et al. Inhaled pharmaceutical drug development: nonclinical considerations and case studies. Inhal Toxicol. 2013;25:219–232.
   PubMed Web of Science ®Google Scholar
• Strack T. The pharmacokinetics of alternative insulin delivery systems. Curr Opin Investig Drugs. 2010;11:394–401.
   PubMedGoogle Scholar
• de Boer AH, Hagedoorn P. The role of disposable inhalers in pulmonary drug delivery. Exp Opin Drug Deliv. 2015;12:143–157.
   PubMed Web of Science ®Google Scholar
• Suwandecha T, Wongpoowarak K, Schrichana T. Computer-aided design of dry powder inhalers using computational fluid dynamics to assess performance. Pharm Dev Technol. 2016;21:54–60.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Woolhouse R, et al. Computational fluid dynamics (CFD) assisted performance evaluation of the Twincer disposable high-dose dry powder inhaler. J Pharm Pharmacol. 2012;64:1316–1325.
   PubMed Web of Science ®Google Scholar
• Ruzycki CA, Javaheri E, Finlay WH. The use of computational fluid dynamics in inhaler design. Exp Opin Drug Deliv. 2013;10:307–323.
   PubMed Web of Science ®Google Scholar
• Behara SRB, Longest PW, Farkas DR, et al. Development and comparison of new high efficiency dry powder inhalers for carrier-free formulations. J Pharm Sci. 2014;103:465–477.
   PubMed Web of Science ®Google Scholar
• Wong W, Fletcher DF, Traini D, et al. The use of computational approaches in inhaler development. Adv Drug Deliv Rev. 2012;64:312–322.
   PubMed Web of Science ®Google Scholar
• Minocchieri S, Burren JM, Bachmann MA, et al. Development of the premature infant nose and throat-model (PrINT-Model): an upper airway replica of a premature neonate for the study of aerosol delivery. Pediatr Res. 2008;64:141–146.
   PubMed Web of Science ®Google Scholar
• Hannemann LA. What is new in asthma: new dry powder inhalers. J Pediatr Health Care. 1999;13:159–165.
   PubMedGoogle Scholar
• Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder inhalers on the market today. Pulm Pharmacol Ther. 2003;16:79–95.
   PubMed Web of Science ®Google Scholar
• Prime D, Atkins PJ, Slater A, et al. Review of dry powder inhalers. Adv Drug Deliv Rev. 1997;26:51–58.
   PubMed Web of Science ®Google Scholar
• Chan HK. Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med. 2006;19:21–27.
   PubMedGoogle Scholar
• Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation and performance. Resp Med. 2002;96:292–304.
   Web of Science ®Google Scholar
• Rootmensen GN, Van Keimpema HM, Jansen HM, et al. Predictors for incorrect inhalation technique: a study using a validated videotape scoring method. J Aerosol Med Pulm Drug Deliv. 2010;23:232–328.
   Web of Science ®Google Scholar
• Parlati C, Colombo P, Buttini F, et al. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res. 2009;26:1084–1092.
   PubMed Web of Science ®Google Scholar
• Fenton C, Keating GM, Ploster GL. Novolizer, a multidose dry powder inhaler. Drugs. 2003;63:2437–2445.
   PubMed Web of Science ®Google Scholar